Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01272
|
|||||
| Drug Name |
Pyrimethamine
|
|||||
| Synonyms |
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine; AZT + Pyrimethamine combination; Aventis Brand of Pyrimethamine; BW 50-63; BW 5063; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprim (TN); Daraprime; Daraprin; Diaminopyritamin; EXR-101; Erbaprelina; Ethylpyrimidine; Fansidar (Pyrimethamine/Sulfadoxine); Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; Khloridin; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; M alocid; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Pirimetamina [INN-Spanish]; Pirimetamina [Spanish]; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethamine (JAN/USP/INN); Pyrimethamine (Pyr); Pyrimethamine Hcl; Pyrimethamine [USAN:INN:BAN:JAN]; Pyrimethaminum; Pyrimethaminum [INN-Latin]; RP 4753; TCMDC-123831; TCMDC-125860; Tindurin; Tindurine; Tinduring; WR 2978; Wellcome Brand of Pyrimethamine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Toxoplasmosis [ICD11:1F57] | Approved | [1] | |||
| Actinomycosis [ICD11:1C10] | Approved | [1] | ||||
| Isosporiasis [ICD11:1A33.Z] | Approved | [1] | ||||
| Therapeutic Class |
Antimalarials
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H13ClN4
|
|||||
| Canonical SMILES |
CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl
|
|||||
| InChI |
InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)
|
|||||
| InChIKey |
WKSAUQYGYAYLPV-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 58-14-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 248.71 | Topological Polar Surface Area | 77.8 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9595
,69611
,602526
,640729
,640732
,642442
,642444
,823186
,855854
,7437605
,7847554
,7886730
,7980441
,8027594
,8027596
,8149512
,8153075
,10321489
,10528164
,11112140
,11335827
,11361066
,11363800
,11366362
,11368924
,11372601
,11374146
,11377086
,11406997
,11455757
,11462038
,11466065
,11467185
,11484408
,11485790
,11488702
,11491516
,11492309
,11494720
,15221150
,17389746
,22395175
,24870381
,26611904
,26679783
,26747011
,26747012
,26751532
,29224066
,46505987
|
|||||
| ChEBI ID |
CHEBI:8673
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MATE1 | Transporter Info | Multidrug and toxin extrusion protein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Pyrimethamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. | |||||
| 3 | Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.